It is essential for clinicians to remain informed about emerging clinical trial opportunities and resulting data that may inform therapeutic strategies, affect clinical guidelines, expand treatment options, and ultimately improve patient quality of life.

The following clinical trials preview features seven U.S.-based, Phase 2 and 3 clinical trials focusing on chronic kidney disease or health issues related to chronic kidney disease. All trials featured below are still recruiting as of April 9, 2026. The anticipated primary completion dates range from August 2026 through October 2027. The trials are arranged in order of their start date.

Quick-View Table of Chronic Kidney Disease Clinical Trials
Study TitlePhaseEstimated EnrollmentStudy StartEstimated Primary Completion
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. (BaxDuo-Baltic)2218December 2025May 2027
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease2465December 2024September 2026
Bone in CKD Alkali Response (BICARb Pilot Trial) (BICARb)2, 3103August 2024August 2026
Patient-driven Management of BP in CKD3160December 2022September 2026
Ferric Citrate and Chronic Kidney Disease in Children (FIT4KID)2160June 2022October 2027
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria (FIONA)3219March 2022July 2027
Combination of Novel Therapies for CKD Comorbid Depression (CONCORD)2201September 2020April 2027
Chronic Kidney Disease Clinical Trials with Upcoming Completion Dates

A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. (BaxDuo-Baltic)

  • Sponsor: AstraZeneca
  • Goal: To measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.
  • Interventions: Baxdrostat/dapagliflozin, Baxdrostat/placebo
  • Primary Outcome Measures: To determine whether baxdrostat/dapagliflozin is superior to baxdrostat/matching placebo at reducing albuminuria.
  • Time Frame: Up to 12 weeks
  • Study Details
  • Source

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

  • Sponsor: Novo Nordisk A/S
  • Goal: The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity.
  • Interventions: NNC0519-0130, placebo, semaglutide
  • Primary Outcome Measures: Change in urinary albumin-to-creatinine ratio (UACR) at week 12; Change in urinary albumin-to-creatinine ratio (UACR) at week 24; Change in urinary albumin-to-creatinine ratio (UACR) at week 36.
  • Time Frame: From baseline (week 0) to end of a given maintenance dose period (week 12); From baseline (week 0) to end of a given maintenance dose period (week 24); From baseline (week 0) to end of a given maintenance dose period (week 36).
  • Study Details
  • Source

Bone in CKD Alkali Response (BICARb Pilot Trial) (BICARb)

  • Sponsor: Albert Einstein College of Medicine
  • Goal: The goal of this clinical trial is to test whether potassium citrate improves skeletal health in adults and children with chronic kidney disease.
  • Interventions: Potassium citrate extended release oral tablet, placebo, potassium citrate and citric acid oral solution
  • Primary Outcome Measures: Change in total volumetric bone mineral density (BMD) - Distal Radius; Change in total volumetric bone mineral density (BMD) - Tibia.
  • Time Frame: Baseline to six months; Baseline to six months.
  • Study Details
  • Source

Patient-Driven Management of BP in CKD

  • Sponsor: VA Office of Research and Development
  • Goal: The proposed research will evaluate if patients managing their blood pressure medications under the guidance of a clinical pharmacist works better to lower blood pressure than patients monitoring their blood pressure at home and the standard care.
  • Interventions: Self-management of BP medications, self-monitoring of home BP
  • Primary Outcome Measures: Change in standardized office BP
  • Time Frame: 12 months
  • Study Details
  • Source

Ferric Citrate and Chronic Kidney Disease in Children (FIT4KID)

  • Sponsor: University of California, Los Angeles
  • Goal: Assess the effects of therapy with ferric citrate on changes in intact FGF23 levels (iFGF23, primary endpoint) in 160 pediatric patients (80 in each of the two arms) aged 6-18 years of either sex with chronic kidney disease stages 3-4 and age-appropriate normal serum phosphate levels.
  • Interventions: Ferric citrate, placebo
  • Primary Outcome Measures: iFGF23 levels; Safety of ferric citrate; Tolerability of ferric citrate.
  • Time Frame: 12 months; 12 months; 12 months.
  • Study Details
  • Source

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria (FIONA)

  • Sponsor: Bayer
  • Goal: The main purpose of this study is to learn more about whether finerenone added to either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers can help reduce the amount of protein in the participants' urine more than a placebo.
  • Interventions: Finerenone (Kerendia, BAY94-8862), placebo
  • Primary Outcome Measures: Percent change in urinary protein-to-creatinine ratio (UPCR) reduction from baseline to day 180+/-7.
  • Time Frame: From baseline to day 180+/-7.
  • Study Details
  • Source

Combination of Novel Therapies for CKD Comorbid Depression (CONCORD)

  • Sponsor: Stony Brook University
  • Goal: The overall goal of the study is to determine if treatment of a major depressive disorder improves the outcomes of patients with chronic kidney disease.
  • Interventions: Bupropion, behavioral activation therapy, placebo, clinical management
  • Primary Outcome Measure: Quick inventory of depressive symptomatology-clinician rated scale (QIDS-C).
  • Time Frame: Assessed at baseline and weeks 4, 6, 8, 12, and 16.
  • Study Details
  • Source
Related Guidelines:

Sign up for alerts and stay informed on the latest published guidelines.